The roundup covers a report that the Trump administration is weighing sales of unapproved peptides, plus a so-called peptide party in India.
Recap by typeshit. Post by Facebook on Facebook.
One study cited by @fittrwithsquats put the risk of non-scarring hair loss about 40% higher with GLP-1 use, mostly telogen effluvium. Nail findings are less consistent.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
The Ministry of Health and Social Services wants careful prescribing and monitoring as public demand for weight loss and metabolic treatments grows.
Our Peak says skin can lag behind when people lose a lot of weight quickly on GLP-1 drugs, since it needs time to remodel.
Loading…